| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/01.FPC.0000230416.82349.90 |
| P698 | PubMed publication ID | 17108811 |
| P50 | author | Mikko Niemi | Q42328966 |
| Mikko Neuvonen | Q43182675 | ||
| P2093 | author name string | Marja K. Pasanen | |
| Pertti J. Neuvonen | |||
| P433 | issue | 12 | |
| P921 | main subject | pharmacokinetics | Q323936 |
| simvastatin | Q670131 | ||
| P304 | page(s) | 873-879 | |
| P577 | publication date | 2006-12-01 | |
| P1433 | published in | Pharmacogenetics and Genomics | Q10534561 |
| P1476 | title | SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid | |
| P478 | volume | 16 |
| Q90020619 | A Genome-wide Association Study of Circulating Levels of Atorvastatin and Its Major Metabolites |
| Q28395802 | A mechanistic, model-based approach to safety assessment in clinical development |
| Q37908891 | A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application? |
| Q46111557 | ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin. |
| Q45993642 | ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. |
| Q36872923 | Acute-onset rhabdomyolysis secondary to sitagliptin and atorvastatin interaction |
| Q57585223 | An African-specific profile of pharmacogene variants for rosuvastatin plasma variability: limited role for SLCO1B1 c.521T>C and ABCG2 c.421A>C |
| Q59528278 | Angeborene Störungen im Lipoproteinstoffwechsel |
| Q33846255 | Applied pharmacogenomics in cardiovascular medicine |
| Q44081116 | Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and Ginkgo biloba extracts in healthy subjects. |
| Q36256049 | Association Between SLCO1B1 Gene T521C Polymorphism and Statin-Related Myopathy Risk: A Meta-Analysis of Case-Control Studies |
| Q28070052 | Association between SLCO1B1 -521T>C and -388A>G polymorphisms and risk of statin-induced adverse drug reactions: A meta-analysis |
| Q46378129 | Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy |
| Q54373168 | Association between statin-induced creatine kinase elevation and genetic polymorphisms in SLCO1B1, ABCB1 and ABCG2. |
| Q35135638 | Association of CYP2D6*10, OATP1B1 A388G, and OATP1B1 T521C polymorphisms and overall survival of breast cancer patients after tamoxifen therapy |
| Q50606686 | Association of polymorphisms in drug transporter genes (SLCO1B1 and SLC10A1) and anti-tuberculosis drug-induced hepatotoxicity in a Chinese cohort |
| Q43826505 | Associations between the genotypes and phenotype of CYP3A and the lipid response to simvastatin in Chinese patients with hypercholesterolemia |
| Q58594415 | Associations of the SLCO1B1 Polymorphisms With Hepatic Function, Baseline Lipid Levels, and Lipid-lowering Response to Simvastatin in Patients With Hyperlipidemia |
| Q35447163 | Cardiovascular pharmacogenomics |
| Q26801183 | Cardiovascular pharmacogenomics: current status and future directions |
| Q34792178 | Cerivastatin, genetic variants, and the risk of rhabdomyolysis |
| Q35234128 | Characterization of organic anion transporting polypeptide 1b2-null mice: essential role in hepatic uptake/toxicity of phalloidin and microcystin-LR. |
| Q93002794 | Children Are Not Small Adults: Specific Findings in Statin Exposure and Response in a Growing Population |
| Q57786888 | Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug-Drug Interaction Evaluation: Perspectives From the International Transporter Consortium |
| Q37808687 | Clinical Relevance of Impaired Nonrenal Drug Clearance in ESRD |
| Q37579733 | Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care |
| Q26849254 | Clinical application of cardiovascular pharmacogenetics |
| Q37818151 | Clinical implications of pharmacogenetic variation on the effects of statins. |
| Q37881964 | Clinical response to statins: mechanism(s) of variable activity and adverse effects |
| Q27011524 | Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation |
| Q53086784 | Clopidogrel Markedly Increases Plasma Concentrations of CYP2C8 Substrate Pioglitazone. |
| Q35964012 | Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study |
| Q40135603 | Comparison of SLCO1B1 sequence variability among German, Turkish, and African populations |
| Q49903283 | Comprehensive Pharmacogenomic Study Reveals an Important Role of UGT1A3 in Montelukast Pharmacokinetics |
| Q24651239 | Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics |
| Q64285882 | Considerations for Implementing Precision Therapeutics for Children |
| Q37960129 | Current understanding of hepatic and intestinal OATP-mediated drug-drug interactions. |
| Q43767845 | Cyclosporine inhibition of hepatic and intestinal CYP3A4, uptake and efflux transporters: application of PBPK modeling in the assessment of drug-drug interaction potential |
| Q34138321 | Decreased exposure of simvastatin and simvastatin acid in a rat model of type 2 diabetes |
| Q41759104 | Development and Application of a Mechanistic Pharmacokinetic Model for Simvastatin and its Active Metabolite Simvastatin Acid Using an Integrated Population PBPK Approach. |
| Q57825140 | Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin |
| Q46813708 | Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide |
| Q43258273 | Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin |
| Q48689626 | Differential effect of genetic variants of Na+-taurocholate co-transporting polypeptide (NTCP) and organic anion-transporting polypeptide 1B1 (OATP1B1) on the uptake of HMG-CoA reductase inhibitors |
| Q42757090 | Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. |
| Q36701911 | Discordant associations between SLCO1B1 521T→C and plasma levels of ritonavir-boosted protease inhibitors in AIDS clinical trials group study A5146. |
| Q36951933 | Drug-drug interaction studies: regulatory guidance and an industry perspective |
| Q91620854 | Drug-drug-gene interactions and adverse drug reactions |
| Q53432800 | Effect of HMGCR variant alleles on low-density lipoprotein cholesterol-lowering response to atorvastatin in healthy Korean subjects. |
| Q51266635 | Effect of polymorphisms in CYP3A4, PPARA, NR1I2, NFKB1, ABCG2 and SLCO1B1 on the pharmacokinetics of lovastatin in healthy Chinese volunteers. |
| Q36620076 | Effects of Fostamatinib on the Pharmacokinetics of Oral Contraceptive, Warfarin, and the Statins Rosuvastatin and Simvastatin: Results From Phase I Clinical Studies |
| Q43164707 | Effects of concomitant therapy with diltiazem on the lipid responses to simvastatin in Chinese subjects |
| Q57500258 | Effects ofGinkgo bilobaextracts on pharmacokinetics and efficacy of atorvastatin based on plasma indices |
| Q35183649 | Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers |
| Q93119620 | Enantiospecific Pharmacogenomics of Fluvastatin |
| Q47247020 | Endogenous metabolites-mediated communication between OAT1/OAT3 and OATP1B1 may explain the association between SLCO1B1 SNPs and methotrexate toxicity. |
| Q21135141 | Enteric microbiome metabolites correlate with response to simvastatin treatment |
| Q50911644 | Epigallocatechin-3-gallate decreases the transport and metabolism of simvastatin in rats. |
| Q36238198 | Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults |
| Q38084901 | Ethnic variability in the plasma exposures of OATP1B1 substrates such as HMG-CoA reductase inhibitors: a kinetic consideration of its mechanism |
| Q30582571 | Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design |
| Q38098452 | Expanding role of pharmacogenomics in the management of cardiovascular disorders |
| Q37603899 | Experimental nonalcoholic steatohepatitis increases exposure to simvastatin hydroxy acid by decreasing hepatic organic anion transporting polypeptide expression |
| Q37646768 | Ezetimibe/simvastatin |
| Q39182431 | Fentanyl pharmacokinetics is not dependent on hepatic uptake by organic anion-transporting polypeptide 1B1 in human beings |
| Q43940364 | Frequency of the SLCO1B1 388A>G and the 521T>C polymorphism in Tanzania genotyped by a new LightCycler®-based method |
| Q47676842 | Genetic and Clinical Factors Are Associated With Statin-Related Myotoxicity of Moderate Severity: A Case-Control Study |
| Q37578563 | Genetic determinants of response to statins |
| Q37481450 | Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs |
| Q38088724 | Genetic risk factors for stroke in the genome-wide association era. |
| Q52801124 | Genetic variation in key genes associated with statin therapy in the Azores Islands (Portugal) healthy population. |
| Q28476093 | Genetic variation in the proximal promoter of ABC and SLC superfamilies: liver and kidney specific expression and promoter activity predict variation |
| Q38167710 | Genetics and personalized medicine--a role in statin therapy? |
| Q36998199 | Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1 |
| Q37120923 | Genetics or environment in drug transport: the case of organic anion transporting polypeptides and adverse drug reactions |
| Q36595293 | Genome-wide study of methotrexate clearance replicates SLCO1B1. |
| Q92904846 | Genomewide Association Study of Statin-Induced Myopathy in Patients Recruited Using the UK Clinical Practice Research Datalink |
| Q98778736 | Genomics and Precision Medicine to Direct Statin Use in the Young |
| Q36393911 | Genotype-based clinical trials in cardiovascular disease |
| Q37474395 | Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects |
| Q39340828 | Global analysis of genetic variation in SLCO1B1. |
| Q36877910 | HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms |
| Q38131449 | HMG-CoA reductase inhibitors in chronic kidney disease |
| Q37680968 | Hepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects |
| Q99604573 | Identification of Glycochenodeoxycholate 3-O-Glucuronide and Glycodeoxycholate 3-O-Glucuronide as Highly Sensitive and Specific OATP1B1 Biomarkers |
| Q43965937 | Identification of the effect of multiple polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid using a population-modeling approach |
| Q36986507 | Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges |
| Q53611791 | Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect? |
| Q34612244 | Impact of OATP transporters on pharmacokinetics |
| Q38663481 | Impact of Pharmacogenetics on Efficacy and Safety of Statin Therapy for Dyslipidemia. |
| Q37855801 | Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins |
| Q38888369 | Impact of Transporter Polymorphisms on Drug Development: Is It Clinically Significant? |
| Q38003174 | Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability - considerations for drug development. |
| Q47652004 | Impact of the OATP1B1 c.521T>C single nucleotide polymorphism on the pharmacokinetics of exemestane in healthy post-menopausal female volunteers |
| Q38888365 | Importance of Hepatic Transporters in Clinical Disposition of Drugs and Their Metabolites |
| Q51694525 | In vitro and clinical evaluation of OATP-mediated drug interaction potential of sacubitril/valsartan (LCZ696). |
| Q48573264 | In vitro/in silico approach in the development of simvastatin-loaded self-microemulsifying drug delivery systems |
| Q35855012 | Individual and Combined Associations of Genetic Variants in CYP3A4, CYP3A5, and SLCO1B1 With Simvastatin and Simvastatin Acid Plasma Concentrations |
| Q35915932 | Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions |
| Q89542318 | Influence of SLCO1B1 polymorphisms on lopinavir Ctrough in Serbian HIV/AIDS patients |
| Q39034284 | Interindividual and interethnic variability in drug disposition: polymorphisms in organic anion transporting polypeptide 1B1 (OATP1B1; SLCO1B1). |
| Q45082643 | International Transporter Consortium commentary on clinically important transporter polymorphisms. |
| Q38379295 | Intestinal and hepatic drug transporters: pharmacokinetic, pathophysiological, and pharmacogenetic roles |
| Q42207349 | Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms |
| Q36287236 | Intracellular drug bioavailability: a new predictor of system dependent drug disposition. |
| Q54278534 | Lack of association between SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals. |
| Q37728163 | Lack of effect of genetic polymorphisms of SLCO1B1 on the lipid-lowering response to pitavastatin in Chinese patients |
| Q41951897 | Loss of multidrug and toxin extrusion 1 (MATE1) is associated with metformin-induced lactic acidosis. |
| Q34570995 | Mechanisms and assessment of statin-related muscular adverse effects |
| Q29616802 | Membrane transporters in drug development |
| Q35332088 | Meta-Analysis of the SLCO1B1 c.521T>C Variant Reveals Slight Influence on the Lipid-Lowering Efficacy of Statins |
| Q37638755 | Metabolic bioactivation and drug-related adverse effects: current status and future directions from a pharmaceutical research perspective |
| Q38858861 | Misoprostol-induced fever and genetic polymorphisms in drug transporters SLCO1B1 and ABCC4 in women of Latin American and European ancestry |
| Q37394474 | More Power to OATP1B1: An Evaluation of Sample Size in Pharmacogenetic Studies Using a Rosuvastatin PBPK Model for Intestinal, Hepatic, and Renal Transporter-Mediated Clearances. |
| Q37399440 | No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin |
| Q36536042 | No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone |
| Q40054814 | Non-synonymous polymorphisms in the human SLCO1B1 gene: an in vitro analysis of SNP c.1929A>C. |
| Q35689076 | Nonalcoholic steatohepatitis in precision medicine: Unraveling the factors that contribute to individual variability |
| Q37489569 | OATP1B1-related drug-drug and drug-gene interactions as potential risk factors for cerivastatin-induced rhabdomyolysis |
| Q27001267 | OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies |
| Q88487480 | Opportunities and Challenges in Cardiovascular Pharmacogenomics: From Discovery to Implementation |
| Q28073319 | Overcoming Challenges With Statin Therapy |
| Q28068014 | Pediatric Statin Administration: Navigating a Frontier with Limited Data |
| Q91672470 | Personalized rosuvastatin therapy in problem patients with partial statin intolerance |
| Q37142852 | Personalized vascular medicine: individualizing drug therapy |
| Q34680467 | Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins |
| Q42423828 | Pharmacogenetic Risk Scores for Perindopril Clinical and Cost Effectiveness in Stable Coronary Artery Disease: When Are We Ready to Implement? |
| Q42936467 | Pharmacogenetic interactions between ABCB1 and SLCO1B1 tagging SNPs and the effectiveness of statins in the prevention of myocardial infarction |
| Q37425335 | Pharmacogenetics and stroke |
| Q47130405 | Pharmacogenetics in Cardiovascular Medicine |
| Q64968253 | Pharmacogenetics in the Treatment of Cardiovascular Diseases and Its Current Progress Regarding Implementation in the Clinical Routine. |
| Q38078188 | Pharmacogenetics in the evaluation of new drugs: a multiregional regulatory perspective |
| Q57302675 | Pharmacogenetics of Adverse Drug Reactions |
| Q38242601 | Pharmacogenetics of membrane transporters: a review of current approaches. |
| Q37074291 | Pharmacogenetics of response to statins |
| Q23919667 | Pharmacogenetics, pharmacogenomics, and individualized medicine |
| Q33600104 | Pharmacogenomic insights into treatment and management of statin-induced myopathy |
| Q92506521 | Pharmacogenomics |
| Q37875115 | Pharmacogenomics and adverse drug reactions: the case of statins |
| Q26997380 | Pharmacogenomics and cardiovascular disease |
| Q27692687 | Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine |
| Q60046975 | Pharmacogenomics of Medications Commonly Used in the Intensive Care Unit |
| Q34987138 | Pharmacogenomics of adverse drug reactions: practical applications and perspectives |
| Q90135702 | Pharmacogenomics: What the Doctor Ordered? |
| Q35309161 | Pharmacogenomics: application to the management of cardiovascular disease |
| Q34976915 | Pharmacogenomics: the genetics of variable drug responses |
| Q34787395 | Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin |
| Q43449319 | Pharmacokinetic interaction studies of co-administration of ticagrelor and atorvastatin or simvastatin in healthy volunteers |
| Q42688670 | Pharmacokinetic interactions between simvastatin and setipiprant, a CRTH2 antagonist |
| Q42562160 | Pharmacokinetics of rosuvastatin in 30 healthy Zimbabwean individuals of African ancestry |
| Q46796142 | Pharmacokinetics of the CYP 3A substrate simvastatin following administration of delayed versus immediate release oral dosage forms |
| Q104100069 | Physiologically Based Precision Dosing Approach for Drug-Drug-Gene Interactions: A Simvastatin Network Analysis |
| Q26829263 | Plasma membrane transporters in modern liver pharmacology |
| Q47597667 | Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics |
| Q39224845 | Precision Cardiovascular Medicine: State of Genetic Testing. |
| Q28083100 | Progress in understanding the genomic basis for adverse drug reactions: a comprehensive review and focus on the role of ethnicity |
| Q35634476 | Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition |
| Q38644870 | Recent developments and future directions for the use of pharmacogenomics in cardiovascular disease treatments |
| Q47793459 | Reduced exposure variability of the CYP3A substrate simvastatin by dose individualization to CYP3A activity |
| Q37473376 | Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors |
| Q37074085 | Role of OATP transporters in the disposition of drugs |
| Q38933872 | Role of gemfibrozil as an inhibitor of CYP2C8 and membrane transporters. |
| Q89022021 | Role of genetics in the prediction of statin-associated muscle symptoms and optimization of statin use and adherence |
| Q40180361 | Role of vitamin D pathway gene polymorphisms on rifampicin plasma and intracellular pharmacokinetics |
| Q41911842 | SLCO1A2, SLCO1B1 and SLCO2B1 polymorphisms influences chloroquine and primaquine treatment in Plasmodium vivax malaria. |
| Q34579035 | SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers |
| Q53099880 | SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case-control study. |
| Q37410969 | SLCO1B1 Polymorphisms and Statin-Induced Myopathy |
| Q36184009 | SLCO1B1 c.388A>G Polymorphism Is Associated with HDL-C Levels in Response to Atorvastatin in Chilean Individuals. |
| Q36480609 | SLCO1B1 genetic variants, long-term low-density lipoprotein cholesterol levels and clinical events in patients following cardiac catheterization |
| Q54559255 | SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia. |
| Q35669829 | SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population |
| Q34047278 | SLCO1B1 rs4149056 polymorphism associated with statin-induced myopathy is differently distributed according to ethnicity in the Brazilian general population: Amerindians as a high risk ethnic group |
| Q33949312 | Safety of statins: an update |
| Q89642081 | Simvastatin intolerance genetic determinants: some features in ethnic Uzbek patients with coronary artery disease |
| Q36916934 | Simvastatin: present and future perspectives |
| Q37951651 | Statin dose in Asians: is pharmacogenetics relevant? |
| Q38430744 | Statin intolerance: diagnosis and remedies |
| Q34608646 | Statin pharmacogenomics: opportunities to improve patient outcomes and healthcare costs with genetic testing |
| Q47407410 | Statin related adverse effects and patient education: a study from resource limited settings |
| Q92156926 | Statin-Related Myotoxicity: A Comprehensive Review of Pharmacokinetic, Pharmacogenomic and Muscle Components |
| Q44739535 | Statin-induced muscle toxicity and susceptibility to malignant hyperthermia and other muscle diseases: a population-based case-control study including 1st and 2nd degree relatives |
| Q37253606 | Statin-induced myopathy in a usual care setting-a prospective observational study of gender differences |
| Q37810986 | The ABCG2 transporter and its relations with the pharmacokinetics, drug interaction and lipid-lowering effects of statins |
| Q36158024 | The SLCO1B1*5 genetic variant is associated with statin-induced side effects |
| Q34216710 | The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. |
| Q34276618 | The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. |
| Q37175829 | The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range |
| Q46664324 | The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo |
| Q40768577 | The effects of a single nucleotide polymorphism in SLCO1B1 on the pharmacodynamics of pravastatin |
| Q37955160 | The evolution of the OATP hepatic uptake transport protein family in DMPK sciences: from obscure liver transporters to key determinants of hepatobiliary clearance. |
| Q37696582 | The genetics of ischaemic stroke |
| Q39349116 | The impact of SLCO1B1 polymorphisms on the plasma concentration of lopinavir and ritonavir in HIV-infected men. |
| Q34613443 | The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy. |
| Q51082870 | The influences of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of simvastatin, in relation to CYP3A4 inhibition. |
| Q38991373 | The role of organic anion transporting polypeptides in drug absorption, distribution, excretion and drug-drug interactions |
| Q37986145 | Towards safer and more predictable drug treatment--reflections from studies of the First BCPT Prize awardee |
| Q37627544 | Transporter pharmacogenetics and statin toxicity |
| Q45243894 | Transporter-Enzyme Interplay: Deconvoluting Effects of Hepatic Transporters and Enzymes on Drug Disposition Using Static and Dynamic Mechanistic Models |
| Q37862576 | Transporter-mediated drug uptake and efflux: important determinants of adverse drug reactions |
| Q37905033 | Transporter-mediated drug-drug interactions |
| Q36294394 | Treatment Options for Statin-Associated Muscle Symptoms |
| Q43268896 | UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo |
| Q38959516 | Uremic toxins enhance statin-induced cytotoxicity in differentiated human rhabdomyosarcoma cells |
Search more.